Diffuse alveolar haemorrhage secondary to warfarin therapy for atrial fibrillation: a case report and literature review

Waness, Abdelkarim; Aldabbagh, Tarek; Harakati, Mohammed S.

doi:10.1136/bcr.08.2008.0757

Cited by 19 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among collagen tissue diseases, Wegener granülomatosis (7,8), systemic lupus erythematosus (9,10) and Goodpasture syndrome (11), give rise to DAH, owing to immune deposits in alveoler interstitium and intra alveolar blood vessels. In addition, drugs such as cocaine, difenylhidantoin and leflunomid may lead to DAH (12). It is determined that, the clinical picture in our cases, is that of DAH, which occurs rarely without any systematic involvement other than pulmonary involvement.…”

Section: Discussionmentioning

confidence: 82%

A Rare Complication related with Oral Anticoagulant Use: Diffuse Alveolar Hemorrhage (Over 65 Years; Four Case Reports)

Duru¹,

Kurt²,

Yumrukuz³

et al. 2016

Respir Case Rep

View full text Add to dashboard Cite

Diffuse alveolar hemorrhage (DAH) caused by immune and non-immune etiological factors, characterized by diffuse alveolar consolidation, often presents with the clinical triad of dyspnea, hemoptysis and, anemia, as a result of the disruption of the alveolocapillary membrane of the lung. We present four cases, when the patients are over 65 years of age, followed up at our clinic with diffuse alveolar hemorrhage as a rare complication of the uncontrolled use of anticoagulant (Warfarin) therapy.

show abstract

Section: Discussionmentioning

confidence: 82%

A Rare Complication related with Oral Anticoagulant Use: Diffuse Alveolar Hemorrhage (Over 65 Years; Four Case Reports)

Duru¹,

Kurt²,

Yumrukuz³

et al. 2016

Respir Case Rep

View full text Add to dashboard Cite

show abstract

“…However, the incidence of DAH in patients receiving anticoagulant therapy is low [5]. DAH secondary to warfarin therapy has been rarely reported [6, 7], but DAH is a serious adverse effect of dabigatran [8] and apixaban [9]. However, DAH associated with edoxaban has not been reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy

Nitta

Imamura

Yashio

et al. 2016

Case Reports in Critical Care

View full text Add to dashboard Cite

Introduction. The main adverse effect of anticoagulant therapy is bleeding, and major bleeding, including intracranial, gastrointestinal, and retroperitoneal bleeding, has been reported as an adverse effect of edoxaban, a direct oral anticoagulant (DOAC). Bleeding during systemic anticoagulation with edoxaban presents a therapeutic conundrum, because there is currently no safe or efficacious reversal agent to stop major bleeding. Case Report. A 51-year-old woman had multiple traumatic injuries, including lower limb fractures. On day 8, she developed deep venous thrombosis, and edoxaban was administered orally. On day 38, she developed fungemia, which was treated with an antifungal drug. On day 43, she presented with dyspnea. Chest computed tomography scan showed bilateral diffuse ground-glass opacities in the whole lung fields. The results of the subsequent workup (i.e., serum levels of the antineutrophil cytoplasmic antibody, antinuclear antibody, and antiglomerular basement membrane antibody) and microbiological study were unremarkable. Based on these findings, her condition was diagnosed as diffuse alveolar hemorrhage (DAH) associated with edoxaban therapy. The lung opacities disappeared spontaneously after edoxaban therapy was discontinued. Conclusion. DAH is a dangerous complication associated with edoxaban therapy. DOACs, including edoxaban, should be prescribed with caution, especially for patients in a critical condition.

show abstract

“…61 Most reports of alveolar hemorrhage in the literature are secondary to warfarin, although newer direct oral anticoagulants (DOACs) have been associated with it. [71][72][73] A case series identified the incidence of rivaroxaban associated with significant alveolar hemorrhage to be 3 in 1,000 patients. 74 Several factors may be contributing to warfarin-induced hemoptysis.…”

Section: Ac-induced Lthmentioning

confidence: 99%

Life-Threatening Hemoptysis

Deshwal

Sinha

Mehta

2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Life-threatening hemoptysis (LTH) is any amount of hemoptysis that causes significant hemodynamic decompensation or respiratory distress which may lead to death if left untreated. While the amount of hemoptysis that qualifies as massive hemoptysis has continued to be debated, any amount between 100 to 1,000 mL/day is considered significant. Up to 15% cases of hemoptysis are LTH and need urgent life-saving intervention. Understanding of pulmonary vascular anatomy is of paramount importance to manage LTH. The goal of treatment lies in airway protection, appropriate oxygenation, and prevention of exsanguination. Once the airway is stabilized, a quick diagnosis and control of bleeding site is targeted. This chapter highlights current practices and approach to LTH including medical management, bronchoscopic approach, and advanced therapies such as bronchial artery embolization and surgical resection. We review situations, such as bronchiectasis, vascular malformation, diffuse alveolar hemorrhage, and tracheostomy bleed and specific approach to management of these conditions in a systematic and evidence-based manner.

show abstract

Diffuse alveolar haemorrhage secondary to warfarin therapy for atrial fibrillation: a case report and literature review

Cited by 19 publications

References 25 publications

A Rare Complication related with Oral Anticoagulant Use: Diffuse Alveolar Hemorrhage (Over 65 Years; Four Case Reports)

A Rare Complication related with Oral Anticoagulant Use: Diffuse Alveolar Hemorrhage (Over 65 Years; Four Case Reports)

Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy

Life-Threatening Hemoptysis

Contact Info

Product

Resources

About